Head-To-Head Contrast: Organogenesis (NASDAQ:ORGO) vs. GRAIL (NASDAQ:GRAL)

GRAIL (NASDAQ:GRAL) and Organogenesis (NASDAQ:ORGO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Volatility and Risk

GRAIL has a beta of 2.86, indicating that its share price is 186% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Insider & Institutional Ownership

49.6% of Organogenesis shares are held by institutional investors. 1.8% of GRAIL shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for GRAIL and Organogenesis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1	6	5	0	2.33
Organogenesis	1	2	0	0	1.67

GRAIL presently has a consensus price target of $121.40, indicating a potential downside of 0.03%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 432.87%. Given Organogenesis’ higher possible upside, analysts clearly believe Organogenesis is more favorable than GRAIL.

Profitability

This table compares GRAIL and Organogenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GRAIL	-243.80%	-15.99%	-14.22%
Organogenesis	-19.94%	-23.89%	-11.13%

Valuation & Earnings

This table compares GRAIL and Organogenesis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26 million	32.82	-$408.35 million	($9.50)	-12.78
Organogenesis	$564.17 million	0.19	$37.03 million	($0.86)	-0.95

Organogenesis has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Summary

Organogenesis beats GRAIL on 9 of the 14 factors compared between the two stocks.

About GRAIL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.